Astrazeneca (AZN) Capital Leases (2017 - 2026)

Astrazeneca has reported Capital Leases for 10 years, with the latest figure at -$182.0 million in Q2 2026.

• On a quarterly basis, Capital Leases rose 1.09% year-over-year to -$182.0 million in Q2 2026; TTM through Jun 2026 was -$182.0 million, a 1.09% increase from a year earlier, with the FY2025 full-year figure at -$372.0 million, down 17.72% from the prior year.
• Capital Leases was -$182.0 million for Q2 2026 at Astrazeneca, down from -$94.0 million in the prior quarter.
• The five-year high for Capital Leases was -$67.0 million in Q1 2023, with the low at -$372.0 million in Q4 2025.
• Average Capital Leases over 5 years is -$179.7 million, with a median of -$166.0 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2023: Capital Leases tumbled 48.0% in 2022, then grew 9.46% in 2023.
• Over 5 years, Capital Leases stood at -$244.0 million in 2022, then decreased by 9.84% to -$268.0 million in 2023, then fell by 17.91% to -$316.0 million in 2024, then decreased by 17.72% to -$372.0 million in 2025, then surged by 51.08% to -$182.0 million in 2026.
• The last three Capital Leases figures came in at -$182.0 million (Q2 2026), -$94.0 million (Q1 2026), and -$372.0 million (Q4 2025), per Business Quant data.